Deal Watch: Salix Merges With Italy’s Cosmo In Latest Tax-Inversion Play
Executive Summary
A research agreement between AstraZeneca and Germany’s Max Planck Institute and a development pact between Portola and Daiichi Sankyo for an adverse-bleeding therapy highlight the week’s deal-making. In addition, HealthCare Royalty Partners announced a new royalty deal with Supernus and reworked its 2012 loan with Raptor, while GlobeImmune went public on its second IPO attempt.